Helius Medical Technologies, INC 8-K filings

Helius Medical Technologies receives a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement and intends to appeal the decision.

Helius Medical Technologies secures $3.7 million through warrant exercises and issues new warrants, pending stockholder approval.

Helius Medical Technologies has secured final Medicare reimbursement rates for its PoNS Controller device, aligning with the preliminary determination.

Helius Medical Technologies has announced its first sale of the PoNS System to the VA Healthcare System, marking a significant step in its market penetration strategy.

Helius Medical Technologies is exploring strategic options, including a potential sale or merger, due to reimbursement challenges with its PoNS device.

Helius Medical Technologies reported a 35% increase in revenue compared to the previous quarter, alongside key advancements in reimbursement and clinical programs.

Helius Medical Technologies has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing it at risk of delisting.

Helius Medical Technologies' stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance and incentive stock options.

Helius Medical Technologies has received confirmation from Nasdaq that it has regained compliance with listing requirements following a recent financing.

Helius Medical Technologies has announced its 2024 Annual Meeting of Stockholders will be held on June 27, 2024, with a record date of May 28, 2024, and a proposal submission deadline of June 10, 2024.

Helius Medical Technologies announced its first quarter 2024 financial results, highlighted by increased revenue and progress towards Medicare reimbursement for its PoNS device.

Helius Medical Technologies has announced the pricing of a public offering to raise approximately $6.4 million through the sale of common stock and warrants.

Helius Medical Technologies has announced preliminary Medicare payment rates for its PoNS device, with a public meeting scheduled to discuss the rates.

Helius Medical Technologies received a notice from Nasdaq stating that it no longer meets the minimum stockholders' equity requirement for continued listing.

Helius Medical Technologies announced its fourth quarter and full year 2023 financial results, highlighted by securing key reimbursement codes for its PoNS device and progress in stroke development.

Helius Medical Technologies has amended its bylaws, reducing the quorum requirement for stockholder meetings and updating rules for director nominations.

Helius Medical Technologies has obtained HCPCS Level II codes for its PoNS device, a significant step towards securing reimbursement for the treatment of gait deficits.

Helius Medical Technologies sold $1.6 million of its Class A common stock through an at-the-market offering program between October 2023 and February 2024.